US FDA approves Sanofi's bleeding disorder therapy
The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...
Fierce Pharma19h
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...
FDA approves Sanofi treatment for hemophilia A or B
The U.S. Food and Drug Administration approved Qfitlia for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult ...
Endpoints News20h
FDA ap­proves Sanofi's RNAi drug for he­mo­phil­ia A and B
FDA approves Sanofi's RNAi hemophilia drug fitusiran, licensed from Alnylam, to treat both hemophilia A and B by lowering ...
Yahoo Finance3d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib (Revised)
A similar regulatory filing for the drug is currently under review by the EMA, which is also supported by data from these studies. Per Sanofi, the above results make tolebrutinib the first and the ...
Sanofi reports tolebrutinib submission accepted for FDA priority review
The U.S. Food and Drug Administration is evaluating under priority review the regulatory submission of tolebrutinib to treat non-relapsing ...
Yahoo Finance4d
FDA Accepts Sanofi's Filing for Multiple Sclerosis Drug Tolebrutinib
A similar regulatory filing for the drug is currently under review by the EMA, which is also supported by data from these studies. Per Sanofi, the above results make tolebrutinib the first and the ...